Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

被引：17

作者：

Gottschalk, Andrea ^{[1
]}

Glauche, Ingmar ^{[1
]}

Cicconi, Silvia ^{[2
]}

Clark, Richard E. ^{[3
]}

Roeder, Ingo ^{[1
,4
]}

机构：

[1] Tech Univ Dresden, Carl Gustav Carus Fac Med, Inst Med Informat & Biometry, Fetscherstr 74, D-01307 Dresden, Germany

[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England

[3] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England

[4] Natl Ctr Tumor Dis, Partner Site Dresden, Dresden, Germany

来源：

BLOOD | 2020年 / 135卷 / 10期

关键词：

CHRONIC MYELOID-LEUKEMIA; IMATINIB;

D O I：

10.1182/blood.2019003395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：766 / 769

页数：4

共 11 条

[11] Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial [J].

Saussele, Susanne ;

Richter, Johan ;

Guilhot, Joelle ;

Gruber, Franz X. ;

Hjorth-Hansen, Henrik ;

Almeida, Antonio ;

Janssen, Jeroen J. W. M. ;

Mayer, Jiri ;

Koskenvesa, Perttu ;

Panayiotidis, Panayiotis ;

Olsson-Stromberg, Ulla ;

Martinez-Lopez, Joaquin ;

Rousselot, Philippe ;

Vestergaard, Hanne ;

Ehrencrona, Hans ;

Kairisto, Veli ;

Polakova, Katerina Machova ;

Mueller, Martin C. ;

Mustjoki, Satu ;

Berger, Marc G. ;

Fabarius, Alice ;

Hofmann, Wolf-Karsten ;

Hochhaus, Andreas ;

Pfirrmann, Markus ;

Mahon, Francois-Xavier .

LANCET ONCOLOGY, 2018, 19 (06) :747-757

← 1 2 →